Aug 2020

ANTG appoints new Business Operations Manager


Australian Natural Therapeutics Group (ANTG), the first and only Australian producer of medicinal cannabis with certified GMP and GACP facilities today announced Beatriz Garabelli has joined the company in the newly created role of Business Operations Manager.

Beatriz has a strong background in an interdisciplinary field of Engineering and Engineering Management.  During her career she has developed core skills in sales, strategic planning, operations, financial planning and business analysis in leadership roles in the US, South America  and Asia Pacific.

Beatriz has held senior roles with IBM, Next Byte, National University of Engineering and during this time became passionate about the power of science and medicine.  She joined Tilray Australia & New Zealand in 2017 where she worked collaboratively with healthcare and pharmaceutical industries, government regulators and research institutions to drive business growth in both countries.

In 2019 Beatriz successfully led National Cannabinoid Clinics in its launch in Australia and helped achieve the goal of allowing patients’ access to high quality cannabinoid therapies.

“We are delighted to welcome Beatriz to our team. Her experience in the local medicinal cannabis industry is crucial to deliver on our vision of providing high quality Australian-grown medicinal cannabis products at an affordable price” says Matthew Cantelo, ANTG CEO. “Her appointment will enable us to achieve our commercial goals while we remain focused on understanding the massive therapeutic potential of medicinal cannabis and bringing that benefit to the community”.

ANTG, an independently owned medicinal cannabis company, has partnered up with leading scientists and academic institutions and is currently sponsoring a number of clinical trials including the use of cannabinoid therapies on various cancers including acute myeloid leukaemia with the University of Newcastle , and pre-dementia studies with NCIM.

Beatriz Garabelli – Business Operations Manager



ANTG’s Eve Cannabis product reveals its potential to kill or inhibit cancer cells without impacting normal cells…


ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).


In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.


We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.